Cite
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
MLA
Thiery-Vuillemin, Antoine, et al. “Pain and Health-Related Quality of Life with Olaparib versus Physician’s Choice of next-Generation Hormonal Drug in Patients with Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-Label, Randomised, Phase 3 Trial.” The Lancet. Oncology, vol. 23, no. 3, Mar. 2022, pp. 393–405. EBSCOhost, https://doi.org/10.1016/S1470-2045(22)00017-1.
APA
Thiery-Vuillemin, A., de Bono, J., Hussain, M., Roubaud, G., Procopio, G., Shore, N., Fizazi, K., Dos Anjos, G., Gravis, G., Joung, J. Y., Matsubara, N., Castellano, D., Degboe, A., Gresty, C., Kang, J., Allen, A., Poehlein, C., & Saad, F. (2022). Pain and health-related quality of life with olaparib versus physician’s choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. The Lancet. Oncology, 23(3), 393–405. https://doi.org/10.1016/S1470-2045(22)00017-1
Chicago
Thiery-Vuillemin, Antoine, Johann de Bono, Maha Hussain, Guilhem Roubaud, Giuseppe Procopio, Neal Shore, Karim Fizazi, et al. 2022. “Pain and Health-Related Quality of Life with Olaparib versus Physician’s Choice of next-Generation Hormonal Drug in Patients with Metastatic Castration-Resistant Prostate Cancer with Homologous Recombination Repair Gene Alterations (PROfound): An Open-Label, Randomised, Phase 3 Trial.” The Lancet. Oncology 23 (3): 393–405. doi:10.1016/S1470-2045(22)00017-1.